These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16690461)

  • 1. Glycemic relapse in type 2 diabetes.
    Graber AL; Shintani AK; Wolff K; Brown A; Elasy TA
    Endocr Pract; 2006; 12(2):145-51. PubMed ID: 16690461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes.
    Lauffenburger JC; Lewey J; Jan S; Lee J; Ghazinouri R; Choudhry NK
    JAMA Netw Open; 2020 Jan; 3(1):e1919645. PubMed ID: 31968115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic relapse in a collaborative primary care-based type 2 diabetes management program.
    Wheeler SE; Struebing T; Drury RLC; Caruso L; Teng BQ; Brazauskas R; Hanson RJ; Crotty BH
    J Am Pharm Assoc (2003); 2021; 61(4):476-483.e3. PubMed ID: 33715974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
    Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic response to newly initiated diabetes therapies.
    Karter AJ; Moffet HH; Liu J; Parker MM; Ahmed AT; Go AS; Selby JV
    Am J Manag Care; 2007 Nov; 13(11):598-606. PubMed ID: 17988185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Daily Glycemic Fluctuations in Patients With Type 2 Diabetes.
    Kushner PR
    J Fam Pract; 2016 Nov; 65(11 Suppl):. PubMed ID: 28087879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes.
    Nichols GA; Kimes TM; Harp JB; Kou TD; Brodovicz KG
    Diabetes Care; 2012 Mar; 35(3):495-7. PubMed ID: 22279033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients.
    Liu J; Liu J; Fang D; Liu L; Huang Z; Wan X; Cao X; Li Y
    Endocr J; 2013; 60(6):725-32. PubMed ID: 23428844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Sorbo SE; Dell'Aquila S; Febo F; Ginestra F; Graziano G; Rossi MC; Consoli A; Formoso G
    Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
    Hayward RA; Manning WG; Kaplan SH; Wagner EH; Greenfield S
    JAMA; 1997 Nov; 278(20):1663-9. PubMed ID: 9388085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L; Herman WH; Strange P; Harris A;
    Diabetes Care; 2006 Jan; 29(1):1-8. PubMed ID: 16373887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy.
    Nichols GA; Koo YH; Shah SN
    J Gen Intern Med; 2007 Apr; 22(4):453-8. PubMed ID: 17372792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus.
    Yki-Järvinen H; Ryysy L; Kauppila M; Kujansuu E; Lahti J; Marjanen T; Niskanen L; Rajala S; Salo S; Seppälä P; Tulokas T; Viikari J; Taskinen MR
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4037-43. PubMed ID: 9398709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.